Pfizer, China Drugmaker Partner to Sell Local Brand of Paxlovid

(Bloomberg) — Pfizer has struck a deal with Chinese drugmaker CSPC Pharmaceutical Group Ltd. to launch a local brand of Covid-19 antiviral Paxlovid, the latest in a string of partnerships the U.S. giant has secured as it expands access in China.

CSPC, which earlier this year won approval from Chinese regulators for the country’s first locally developed mRNA Covid vaccine, will manufacture and sell the medication in the Chinese mainland, according to a Pfizer spokesperson. The antiviral is used to treat Covid-positive people who are at higher risk of severe illness, hospitalization and death.